GLP-1 and Addiction: Alcohol Cravings, Substance Use, and Research

You may have read that GLP-1 medications like semaglutide reduce cravings not just for food, but for alcohol, nicotine, and other substances. Some patients report this directly. Others wonder if this is hype or if there is real science behind it. Here is what the research actually shows, what it means for you, and why this is an active and genuinely important area of medical investigation.

Why GLP-1 affects cravings beyond food

GLP-1 receptors are not unique to your appetite system. They are distributed throughout your brain, including in the exact circuits that drive addiction and reward-seeking behavior.

The mesolimbic dopamine system is your brain’s reward pathway. It is the “wanting” system that tells you something is desirable and worth pursuing. This system is activated by food, alcohol, nicotine, drugs, gambling, and other reward-driven behaviors. Highly palatable foods activate it. So does alcohol, nicotine, and opioids. The dopamine neurons in the ventral tegmental area and nucleus accumbens fire when you see, smell, or think about these things.^[1] That firing is what produces the craving, the pull, the desire to use.

GLP-1 receptors are present throughout these reward circuits.^[1] When GLP-1 agonists bind to receptors in these brain regions, they appear to dampen the dopamine-driven signal. The pull toward reward-seeking behavior becomes quieter. This is the same mechanism that reduces food noise, but it is not specific to food. If dopamine signaling is dampened, the effect extends to other reward-driven behaviors: alcohol, nicotine, gambling, shopping, or other substance use.

This mechanistic foundation is why researchers became interested in testing GLP-1 for addiction. It is not speculation. It is biology.

What the evidence shows for alcohol

The most developed research is on alcohol use. Here is where the field stands as of April 2026.

Animal studies have been straightforward. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) has funded multiple studies in rodent models showing that GLP-1 receptor agonists reduce alcohol consumption and alcohol-seeking behavior.^[2] The effects are robust and reliable. This prompted human research.

Observational human studies have found associations consistent with the animal data. Researchers have examined insurance claims and patient populations on GLP-1 medications and found lower rates of alcohol use and alcohol-related diagnoses compared to matched controls not on GLP-1. One notable study published in JAMA Psychiatry in 2023 found that semaglutide use was associated with significantly lower odds of an alcohol use disorder diagnosis compared to people matched for age, weight, and other relevant factors.^[3]

Clinical trials are now underway. The most prominent is the STAR trial (NCT05186142), a phase 2 study testing semaglutide specifically for alcohol use disorder.^[4] Results from this and other ongoing trials are expected to report in 2026 and 2027.

None of this means GLP-1 medications are currently approved for alcohol use disorder. They are not. But the research direction is serious, well-funded, and the early signals are positive enough that this is now a legitimate treatment investigation.

What the evidence shows for other substances

The research on nicotine is less developed than alcohol but moving in the same direction. Observational data suggests possible reduction in smoking rates among GLP-1 users. Clinical trials are being planned. The mechanism is plausible (nicotine addiction also involves dopamine reward circuits), but solid clinical evidence does not yet exist.

For opioids, cannabinoids, and other substances, the research is much earlier. Preclinical studies and very early human observations suggest potential, but clinical trials are not yet underway in most cases.^[5] This is a field moving fast.

The unifying theme: the evidence is limited but promising enough that major academic medical centers and the National Institutes of Health are investing in research. This is not fringe speculation. This is mainstream clinical science.

What patients actually report

Beyond the formal research, patients themselves report real experiences.

Many patients spontaneously notice that they no longer want to drink the way they used to. The desire simply quiets. A patient who used to have several drinks most evenings finds themselves having one or two and genuinely not wanting more. Another patient finds that alcohol no longer appeals to them at all. The wanting signal is gone.

Similar patterns have been reported with nicotine. Some patients who smoked regularly report dramatically reduced cigarette cravings, or find that they simply do not think about smoking anymore. Others report reduced gambling, shopping compulsions, or other reward-driven behaviors.

These are patient-reported observations, not clinical evidence of efficacy for treating these conditions. But they are consistent with the mechanism and with the early research findings. And they matter because they suggest the medication’s effects on the reward system are real and noticeable to the people experiencing them.

The variation is important to name. Some patients notice dramatic changes in craving intensity. Others notice nothing. The effect appears to depend on baseline reward-seeking behavior, individual neurobiology, dose, and other factors we do not yet fully understand. Do not expect this benefit. But if you experience it, it is real and worth mentioning to your provider.

What this does not mean

It is critical to be clear about what reduced cravings on GLP-1 does and does not mean.

Reduced craving is not the same as addiction treatment. GLP-1 medications are not being prescribed to treat addiction. They are prescribed for weight management (or diabetes). If you have an active alcohol use disorder or other substance use disorder, evidence-based addiction treatment (therapy, support groups, medications like naltrexone or acamprosate, residential treatment, or combinations of these) remains the appropriate standard of care.

That said, the research suggests GLP-1 might eventually be used as an adjunct to addiction treatment, not a replacement for it. There are clinical trials specifically testing this combination. If you have a substance use disorder and are noticing a significant reduction in cravings on GLP-1, this is worth discussing with both your addiction specialist and your GLP-1 provider. They can coordinate care.

GLP-1 is not a miracle cure for addiction. But it may become one tool in a broader toolkit. We are genuinely in the research phase on this question.

Is GLP-1 medication itself addictive?

This is an important question that comes up, so let me answer it directly.

GLP-1 medications are not controlled substances. They do not produce euphoria or the kind of drug-seeking behavior that characterizes addiction. When people stop taking them, they do not experience physical withdrawal in the clinical sense (sweating, tremors, seizures, cravings for the drug itself).

The main biological consequence of stopping GLP-1 medication is weight regain. Your appetite returns to baseline. Your brain’s baseline reward signaling resumes. But that is not addiction. That is biological response to stopping a medication.

The concept of “dependence” is sometimes confused with addiction. You can be biologically dependent on something (your body needs it to function normally) without being addicted (without experiencing compulsive drug-seeking behavior). Insulin-dependent diabetics are dependent on insulin but not addicted to it. The same distinction applies to GLP-1 medications.

What to do if you notice reduced cravings

If you are on a GLP-1 medication and you notice reduced cravings for alcohol, nicotine, or other substances, here is what matters.

First, mention it to your provider. It is clinically relevant information that helps your provider understand how your brain and body are responding to the medication.

Second, do not use this observation as permission to stop other treatments you are on. If you are in therapy for substance use, keep going. If you are on medication for addiction, do not stop without your provider’s guidance.

Third, take it seriously as a data point. If your relationship with a substance changes significantly on GLP-1, that is information. Pay attention to it. Track it. Be honest about it.

And finally, understand that this is an area of active research. You are living through the early stages of understanding a phenomenon that may eventually become a legitimate part of addiction treatment. Your experience matters.

The distinction between “interesting research” and “approved treatment”

This entire area is worth a final clarity statement.

GLP-1 medications are generating a lot of interest and a lot of hype. Some of that interest is legitimate. Multiple well-funded clinical trials are now testing GLP-1 for substance use disorders. The mechanistic plausibility is high. The early observational signals are promising.

But we do not yet have the evidence to say GLP-1 treats addiction. We do not have FDA approval for this indication. We have early-stage research, preliminary findings, and patient observations that suggest this might be worth investigating. That is different from proven treatment.

The responsible way to talk about this is: GLP-1 medications have shown promise for reducing alcohol and substance cravings in preliminary research and patient observation. This is an active area of investigation. If you notice changes in your own craving patterns on GLP-1, discuss this with your provider. But do not expect this benefit, and do not use GLP-1 as a substitute for evidence-based addiction treatment.

Citations

[1] GLP-1 Therapeutics and their emerging role in alcohol and substance use disorders: an endocrinology primer. Journal of Neuroendocrinology. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC12509273/

[2] The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Pharmaceutical Research. 2021;38(4):577-590. https://pubmed.ncbi.nlm.nih.gov/34532853/

[3] Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. April 2025;82(4):439-447. https://pubmed.ncbi.nlm.nih.gov/39937469/

[4] Semaglutide Therapy for Alcohol Reduction (STAR). ClinicalTrials.gov Identifier: NCT05186142. https://clinicaltrials.gov/study/NCT05186142

[5] GLP-1 receptor agonists: promising therapeutic targets for alcohol use disorder. Endocrinology. 2024;166(4):bqaf028. https://academic.oup.com/endo/article/166/4/bqaf028/8029141